Explore more publications!
Health Monitor Liechtenstein
Got News to Share?

Press Releases

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
July 28, 2025

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Indeterminate GlobeNewswire, Inc.
Liechtenstein Reaffirms Global Leadership in Stability and Philanthropy
June 9, 2025

Liechtenstein Reaffirms Global Leadership in Stability and Philanthropy

Neutral EIN Presswire
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
April 15, 2025

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Indeterminate GlobeNewswire, Inc.
4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion
March 17, 2025

4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion

Indeterminate GlobeNewswire, Inc.
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
November 4, 2025

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

Indeterminate GlobeNewswire, Inc.
bonyf AG receives the EU-MDR Certification Class IIa for PerioCream
October 16, 2025

bonyf AG receives the EU-MDR Certification Class IIa for PerioCream

Neutral EIN Presswire
ThinkCareBelieve: Week 43 of America's Climb into the Golden Age
November 15, 2025

ThinkCareBelieve: Week 43 of America's Climb into the Golden Age

Indeterminate GlobeNewswire, Inc.
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
July 21, 2025

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Indeterminate GlobeNewswire, Inc.
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
August 19, 2025

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Indeterminate GlobeNewswire, Inc.
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
June 20, 2025

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

Indeterminate GlobeNewswire, Inc.
PureCycle Receives REACH Certification, Unlocking EU Sales of PureFive™ Resin
October 14, 2025

PureCycle Receives REACH Certification, Unlocking EU Sales of PureFive™ Resin

Indeterminate GlobeNewswire, Inc.
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
April 28, 2025

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Indeterminate GlobeNewswire, Inc.
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
June 6, 2025

European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy

Indeterminate GlobeNewswire, Inc.
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
May 23, 2025

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Indeterminate GlobeNewswire, Inc.
SEALSQ and Kaynes SemiCon Announce Joint Venture to Establish India's First Secure Semiconductor Center for Onshore Personalization and Quantum-Resistant Technology
September 29, 2025

SEALSQ and Kaynes SemiCon Announce Joint Venture to Establish India's First Secure Semiconductor Center for Onshore Personalization and Quantum-Resistant Technology

Indeterminate GlobeNewswire, Inc.
Ligand Reports First Quarter 2025 Financial Results
May 8, 2025

Ligand Reports First Quarter 2025 Financial Results

Indeterminate GlobeNewswire, Inc.
Steam Boiler Systems Market USD 16.86 Billion in 2024 – Growth, Trends & Regional Insights
September 30, 2025

Steam Boiler Systems Market USD 16.86 Billion in 2024 – Growth, Trends & Regional Insights

Neutral EIN Presswire
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
February 28, 2025

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Indeterminate GlobeNewswire, Inc.
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
April 28, 2025

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Indeterminate GlobeNewswire, Inc.
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
April 16, 2025

Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025

Indeterminate GlobeNewswire, Inc.
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions